Reprogramming of Tumor Stroma to Enhance Cancer Immunotherapy

Información del proyecto

REACT

Identificador del acuerdo de subvención: 101158040

DOI

10.3030/101158040

Proyecto cerrado

Fecha de la firma de la CE 12 Marzo 2024

Fecha de inicio 1 Junio 2024

Fecha de finalización 30 Noviembre 2025

Financiado con arreglo a

• European Research Council (ERC)

Coste total

Sin datos

Aportación de la UE

€ 150 000,00

Coordinado por

INSTITUT PASTEUR
France

Periodic Reporting for period 1 - REACT (Reprogramming of Tumor Stroma to Enhance Cancer Immunotherapy)

Período documentado: 2024-06-01 hasta 2025-11-30

Resumen del contexto y de los objetivos generales del proyecto

Immunotherapies such as immune checkpoint inhibitors (ICIs) and CAR T cells can induce durable responses in some cancers, yet their efficacy in solid tumors remains limited. A major driver of resistance is the hostile tumor microenvironment (TME), which restricts effector immune-cell infiltration or can suppress their function even after they reach the tumor. Although several combination strategies have been developed to boost immunotherapy activity, many are associated with substantial toxicity, underscoring the need for new approaches that selectively target TME components that shape anti-tumor immunity.

Building on our ERC Consolidator Grant project, the overall objectives of this proposal were to develop novel therapeutic strategies targeting structural components of the TME and evaluate combination regimens designed to enhance the efficacy of immunotherapies in solid tumors.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

During this project, we characterized therapeutic agents targeting the TME of solid tumors in collaboration with industrial partners. Our key achievements were the identification of lead agent candidates that induced anti-tumor activity in vivo, together with the optimization of a window for co-treatment when combined with current standard therapies. In parallel, we initiated collaborations with experts to expand the translational aspects of these efforts

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

We identified novel therapeutic agents to improve the treatment of solid tumors. These findings have generated renewed interest from potential investors and industrial partners to further advance this concept and, potentially, extend it to additional mechanisms of resistance in solid tumors, opening new avenues for research and therapeutic development.